Natural course of diabetic nephropathy in type 1 diabetes
1. Introduction
Diabetes mellitus (DM) is a group of metabolic diseases characterized with inappropriate hyperglycemia due to either a deficiency of insulin secretion or a combination of insulin resistance and inadequate insulin secretion (Masharani, 2008). Type 1 diabetes is caused by absolute deficiency of insulin secretion. Individuals at risk of developing this type of diabetes are found with serologic evidence of an autoimmune process occurring in the pancreatic islets and by genetic markers. In type 2 diabetes, it is a combination of resistance to insulin action and an inadequate compensatory insulin secretion response (American Diabetes Association, 2008). Diabetic nephropathy, one of the common complications of diabetes, has become the leading cause of end-stage renal failure in many countries (Chen et al., 2005). In general, about 1 out of 3 patients with type 1 or type 2 diabetes proceed to developing significant diabetic nephropathy (Zipp and Schelling, 2003). It is believed that the pathophysiologic mechanisms of renal disorder are similar in both types of diabetes (Kern et al., 1999). The pathogenesis and clinical course of diabetic nephropathy can be monitored by structural and hemodynamic changes. The earliest changes is an increase in glomerular filtration rate (GFR), also call “hyperfiltration” stage, which is followed by detectable glomerular lesions with normal albumin excretion rate. The next change is the development of microalbuminuria. Once microalbuminuria persist, both changes in glomerular structure, such as mesangial expansion and basement membrane thickening, and permeability happened, which is referred as “incipient nephropathy”. Diabetic subjects with persistent microalbuminuria are at increased risk for “overt diabetic nephropathy”. At this stage, prominent proteinuria, hypertension, and renal insufficiency progressed. The pathological findings in this stage are glomerular basement membrane (GBM) thickening, mesangial expansion and resulting in diffuse and/or nodular glomerulosclerosis, afferent and efferent arteriolar hyalinosis, and tubulointerstitial fibrosis (Cooper and Gilbert, 2003). After several years of persistent proteinuria, progression to end-stage renal disease will occur (Caramori and Mauer, 2001). Advanced diabetic glomerulopathy is commonly characterized by diffuse glomerulosclerosis and may sometimes exhibit a distinctive morphological appearance, namely, the nodular form of glomerulosclerosis, as first described by Kimmelstiel and Wilson in 1936 (Kimmelstiel and Wilson, 1936; Kern et al., 1999). The stages of diabetic nephropathy are shown in Table 1 (Vora and Ibrahim, 2003).
|
|
1 | Renal hyperfiltration (GFR↑) Renal hypertrophy |
2 | Silent stage Renal hyperfiltration (GFR*↑); Normal UAER*, blood pressure Early histologic changes: non-specific increase in basement membrane thickness, increase mesangial matrix |
3 | Microalbuminuria (UAER 30-300mg/24 h) or incipient nephropathy GFR may elevated or reduced into normal range. Histology: mesangial expansion, glomerular basement membrane thickening, arteriolar hyalinosis |
4 | Established or overt nephropathy (Proteinuria, nephrotic syndrome) GFR decline, Hypertension Histology: mesangial nodules (Kimmelstiel-Wilson lesions), tubulointerstitial fibrosis |
5 | ESRD*** |
The current strategies to treat diabetic nephropathy include intensive glycemic control, antihypertensive treatment with a particular focus on the interruption of renin-angiotensin-aldosterone system (RAS), restriction of dietary protein, and treatment of hyperlipidemia. There are several new approaches to the treatment of diabetic nephropathy based on an ever-growing mechanistic understanding of the causes of diabetic nephropathy by the specific pathogenic roles. These agents include pharmacologic inhibitors of advanced glycation end products (AGEs) formation, protein kinase C (PKC), oxidative stress, and transforming growth factor β (TGF-β) (Williams and Stanton, 2005).
2. Animal models of diabetes mellitus
Type 1 diabetes mellitus is typically an immune mediated destruction of the pancreatic
β cells. Type 2 diabetes mellitus is characterized by insulin resistance and insulin secretion impairment. Animal models have been used extensively in the field of diabetes study. The current available animal models of type 1 and type 2 diabetes are shown in Table 2 (Rees and Alcolado, 2005).
Type 1 | BB (Bio breeding) rat Chinese hamster Celebes black ape Keeshond dog LETL (Long Evans Tokushima lean) rat New Zeland white rabbit NOD (non-obese diabetic) mouse Streptozotocin-induced rats |
Type 2 | CBA/Ca mouse db/db mouse Diabetic Torri rat GK (GotoKakizaki) rat Israeli sand rat KK mouse New Zeland obese mouse NSY (Nagoya-Shibata-Yasuda) mouse Ob/Ob mouse OLETF (Otsuka Long-Evans Tokushima fatty) rat Zucker rat |
3. The molecular mechanism of oxidative stress in diabetic nephropathy
There are four major biochemical pathways considered to lead to the development of diabetic complications associated with hyperglycemia, (1) the polyol pathway, glucose is converted to sorbitol and then metabolized to fructose. Advanced glycation end products (AGE) and reactive oxygen species (ROS) formation also occurs via this pathway, (2) the hexosamine pathway, fructose-6-phosphate is converted to glucosamine intermediates and the production of ROS is subsequently increased, (3) the protein kinase C (PKC) pathway, glucose is converted to glyceraldehyde-3-phosphate and leads to the formation of diacylglycerol (DAG). The elevation of intracellular DAG levels activate PKC, and then activate NADPH oxidase to induce ROS, (4) the formation of advanced glycation end products (AGEs), interaction of AGEs with the receptors of advanced glycation end-products (RAGE) results in ROS activation (Stirban et al., 2008; Shah et al., 2009; Forbes et al., 2008; Brownlee, 2005; Kanwar et al., 2008; Singh et al., 2011).
Increased oxidative stress has been a widely accepted participant in the development and progression of diabetes and its complications (Maritim et al., 2003). ROS are activated in glomerular mesangial and tubular epithelial cells by high glucose, AGE, and cytokines (Park et al., 1999). Hyperglycemia activates the glycolytic pathway and excess generation of mitochondrial ROS initiates a vicious circle by activating several signaling to increase protein kinase C (PKC), and stimulating NADPH oxidase to induce ROS generation (Johansen et al., 2005). Free radicals has been found to be formed disproportionately increase in diabetic subjects by glucose oxidation, nonenzymaticglycation of proteins, and then oxidative degradation of glycated proteins. Excessively amount of free radicals induce damage to cellular proteins, membrane lipids, nucleic acids, and then cell death (Maritim et al., 2003). Besides, increased ROS can cause vascular endothelium abnormalities, reacting directly with nitric oxide (NO) to produce cytotoxic peroxynitrite and increasing reactivity to vasoconstrictors and modification of extracellular matrix proteins (Schnackenberg, 2002). ROS can also damage endothelial cells indirectly by stimulating expression of various genes involved in inflammatory pathway (Baldwin, 1996). Previous study finds that high glucose induces ROS and then up-regulates TGF-β1 and extracellular matrix (ECM) expression in the glomerular mesangial cell (Lee et al., 2003). There are also evidences that antioxidants can effectively inhibit high glucose induced TGF-β1 and fibronectin up-regulation (Ha et al., 1997). Ha et al. (2002) reported that ROS mediate high glucose-induced activation of NF-κB and NF-κB dependent monocyte chemoattractant protein (MCP)-1 expression. NF-κB, a nuclear transcription factor, can initiate the transcription of genes associated with inflammatory response. It is induced by various cell stress-associated stimuli including growth factors, vasoactive agents, cytokines, and oxidative stress (Kuhad and Chopra, 2009). Advanced glycation end products induced by hyperglycemia stimulate NF-κB activation, which sustains the activation of NF-κB in diabetes (Gao et al., 2006). Increased steady-state mRNA levels of inflammatory genes have been shown to associate with interstitial fibrosis and progressive human diabetic nephropathy (Kuhad and Chopra, 2009).
TGF-β plays an important role in the development of renal hypertrophy and accumulation of extracellular matrix (ECM) components in diabetes mellitus (Wolf and Ziyadeh, 1999). The expression of TGF-β was found increased in diabetic nephropathy of experimental animals and in humans (Park et al., 1997; Yamamoto et al., 1993; Sharma et al., 1997; Shankland et al., 1994). Treatment with anti-TGF-β antibody has been documented that it attenuated the effect of high glucose induced cellular hypertrophy
4. Improvement of antioxidantive status in diabetic nephropathy
There are many evidences suggest that ROS play an important role in the pathogenesis of diabetic nephropathy (Rosen et al., 2001). To prevent the development and progression of diabetic nephropathy, it would be effective in combing the strategies to prevent overproduction of ROS and to increase the removal of preformed ROS. (Ha et al., 2008). Some natural products were proved to possess the ability to decelerate diabetic nephropathy via reducing oxidative status. The flower of
On the other hand, some evidences show the exogenous or endogenous antioxidants also can reduce diabetic nephropathy. Oxidative stress via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and vascular endothelial growth factor (VEGF) pathway are documented to play important roles in the development of diabetic nephropathy. Nam et al. (2009) showed the effects of apocynin, a NADPH oxidase inhibitor, on diabetic nephropathy. They found that apocynincan not significantly decrease serum glucose levels but reduce urinary protein and albumin excretions. It is improved in glomerular and mesangial expansion as the apocynin treatment. Apocynin also decreased glomerular VEGF expression and reduced the concentration of 24 h urinary 8-OHdG and MDA. Additionally, Lee et al. (2005) demonstrated that antioxidant taurine prevented glomerular hypertrophy, mesangial expansion, and proteinuria in diabetic rats. Overexpression of catalytic antioxidants was also shown to protect against diabetic injury in several transgenic animals. Craven et al. (2001) showed that diabetic mice transgenic for Cu/Zn SOD had significantly lower urinary albumin excretion, glomerular hypertrophy, and glomerular expression of TGF-β1 and collagen IV protein compared to non-transgenic mice. Hamada et al. (2007) demonstrated that overexpression a small antioxidant, thioredoxin 1, effectively inhibited 8-OHdG in the kidney, albuminuria, mesangial expansion, and tubular injury in diabetic mice. Du et al. (2003) found that overexpression of MnSOD in bovine aortic endothelial cells prevented high glucose-induced activation of PKC, NK-kB, hexosamine, and advanced glycation end product (AGE) pathways. Brezniceanu et al. (2007) demonstrated that renal catalase overexpression in db/db mice attenuated ROS generation, angiotensinogen, proapoptotic gene expression and apoptosis in the kidneys of diabetic mice
Although strict glycemic control is very important in DM patients, many of the current standard therapeutic approaches may also ameliorate oxidative stress as pleiotropic effects (Singh et al., 2011), such as angiotensin-2 converting enzyme (ACE) inhibitors(Kobayashi et al., 2006), angiotensin-2 receptor blockers (ARB) (Ogawa et al., 2006) and aldosterone blockers (spironolactone) (Takebayashi et al., 2006). They activate eNOS to increase bioavailability of nitric oxide, inhibit synthesis of angiotensin 2 and TGF-β and to decelerate or prevent tubulointerstitial fibrosis in diabetic nephropathy, accompanied with control of systemic and intrarenal blood pressure. Cilostazol is a specific inhibitor of phosphodiesterase 3 (PDE 3). Its major effects are prevention of platelet aggregation and dilation of blood vessels via an increase in tissue cAMP levels (Matsumoto et al., 2005). Cilostazol was shown to inhibit vascular smooth muscle cell proliferation
References
- 1.
American Diabetes Association 2008 Diagnosis and classification of diabetes mellitus.Diabetes Care31: S55 S60. - 2.
Babaei-Jadidi R. Karachalias N. Ahmed N. Battah S. Thornalley P. J. 2003 Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. 52 2110 2120 - 3.
Baldwin AS Jr 1996 The NF-KB and IKB proteins: new discoveries and insights. Annu Rev Immunol14 649 683 - 4.
Brezniceanu M. L. Liu F. Wei C. C. Tran S. Sachetelli S. Zhang S. L. Guo D. F. Filep J. G. Ingefinger J. R. Chan J. S. 2007 Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int71 912 923 - 5.
Brownlee M. 2005 The pathobiology of diabetic complications: a unifying mechanism. 54 1615 1625 - 6.
Caramori M. L. Mauer M. 2001 Diabetic nephropathy. in Primer on kidney diseases,3rd edition (Greenberg A, Cheung AK, Coffman TM, Falk RJ, and Jennette JC eds)212 218 National Kidney Fundation, Florida. - 7.
Chang YC, Huang KX, Huang AC, Ho YC, and Wang CJ 2006 Hibiscus anthocyanins- rich extract inhibited LDL oxidation and oxLDL-mediated macrophages apoptosi s. Food ChemToxicol44 1015 1023 - 8.
Chen CC, Hsu JD, Wang SF, Chiang HC, Yang MY, Kao ES, Ho YC, and Wang CJ 2003 Hibiscus sabdariffaExtract inhibits the development of atherosclerosis in cholesterol-fed rabbits. J Agric Food Chem51 5472 5477 - 9.
Chen HC, Guh JY, Chang JM, Hsieh MC, Shin SJ, and Lai YH 2005 Role of lipid control in diabetic nephropathy. Kidney IntSuppl94: S60 S62. - 10.
Comporti M. 1985 Lipid peroxidation and cellular damage in toxic liver injury.Lab Invest53 599 623 - 11.
Cooper ME, and Gilbert RE 2003 Pathogenesis, prevention, and treatment of di abetic nephropathy, In Comprehensive clinical nephrology 2nd edition (Johnson RJ, and Feehally J, eds)439 450 Mosby, Edinburgh. - 12.
Craven PA, Melhem MF, Phillips SL, and DeRubertis FR 2001 Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. 50 2114 2125 - 13.
Du X. Matsumura T. Edelstein D. Rossetti L. Zsengelle´ r. Z. Szabo´ C. Brownlee M. 2003 Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest112 1049 1057 - 14.
Endres M. Laufs U. 2004 Effects of statins on endothelium and signaling mechanisms. Stroke35 (Suppl 1):2708 EOF 11 EOF - 15.
Forbes JM, Coughlan MT, and Cooper ME 2008 Oxidative stress as a major culprit in kidney disease in diabetes 1446 1454 - 16.
Gao L. Wang F. Wang B. Gong B. Zhang J. Zhang X. Zhao J. 2006 Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-KB-dependent down-regulation of vascular cell adhesion molecule-1 expression. J PharmacolExpTher318 53 58 - 17.
Ha H. Lee S. H. Kim K. H. 1997 Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor-β and fibronectin, and lipid peroxidation induced by high glucose in cultured mesangial cells. J PharmacolExpTher281 1457 1462 - 18.
Ha H. Yu M. R. Choi Y. J. Kitamura M. Lee H. B. 2002 Role of high glucose-induced nuclear factor-KB activation in monocyte chemoattractant protein-I expression by mesangial cells. J Am SocNephrol13 894 902 - 19.
Ha H. Hwang I. A. Park J. H. Lee H. B. 2008 Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res ClinPract82 Suppl 1: S42 5 - 20.
Haji Faraji. M. Haji Tarkhani. A. 1999 The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. J Ethnopharmacol65 231 236 - 21.
Hamada Y. Miyata S. Nii-Kono T. Kitazawa R. Kitazawa S. Higo S. Fukunaga M. Ueyama S. Nakamura H. Yodoi J. Fukagawa M. Kasuga M. 2007 Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol Dial Transplant22 1547 1557 - 22.
Harman D. 1981 The aging process. ProcNatlAcadSci USA78 7124 7128 - 23.
Ishizaka N. Taguchi J. Kimura Y. Ikari Y. Aizawa T. Togo M. Miki K. Kurokawa K. Ohno M. 1999 Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. 142 41 46 - 24.
Jang S. Kelley K. W. Johnson R. W. 2008 Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1 ProcNatlAcadSci USA105 7534 7539 - 25.
Jeroudi M. O. Hartley C. J. Bolli R. 1994 Myocardial reperfusion injury: role of oxygen radicals and potential therapy with antioxidants. Am J Cardiol73:2B EOF 7B EOF - 26.
Johansen J. S. Harris A. K. Rychly D. J. Ergul A. 2005 Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice CardiovascDiabetol4: 5. - 27.
Kanwar Y. S. Wada J. Sun L. Xie P. Wallner E. I. Chen S. Chugh S. Danesh F. R. 2008 Diabetic nephropathy: mechanisms of renal disease progression. ExpBiol Med233 4 11 - 28.
Kern W. F. Laszik Z. G. Nadasdy T. Silva F. G. Bane B. L. Pitha J. V. 1999 The kidney in metabolic disorder-- diabetes mellitus, hyperuricemia, oxalosis, nephrocalcinosis, and nephrolithiasis. in Atlas of renal pathology ( Kern WF, Laszik ZG, Nadasdy T, Silva FG, Bane BL, and Pitha JV, eds)97 112 W.B. Saunders company, Philadelphia. - 29.
Kimmelstiel P. Wilson C. 1936 Intercapillary lesions in glomeruli of the kidney. Am J Pathol12 83 97 - 30.
Kobayashi N. Honda T. Yoshida K. Nakano S. Ohno T. Tsubokou T. Matsuoka H. (200 2006 Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition 187 92 100 - 31.
Kuhad A. Chopra K. 2009 Attenuation of diabetic nephropathy by tocotrienol: involvement of NF-KB signaling pathway. Life Sci84 296 301 - 32.
Lee E. A. Seo J. Y. Jiang Z. Yu M. R. Kwon M. K. Ha H. Lee H. B. 2005 Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 upregulation in mesangial cells and in diabetic kidney. Kidney Int67 1762 1771 - 33.
Lee H. B. Yu M. R. Yang Y. Jiang Z. Ha H. 2003 Reactive oxygen species-regulated signaling pathways in diabetic nephropathy.J Am SocNephrol14: S241 245 - 34.
Lee W. C. Chen H. C. Wang C. Y. Lin P. Y. Ou T. T. Chen C. C. Wen M. C. Wang J. Lee H. J. 2010 Cilostazol ameliorates nephropathy in type 1 diabetic rats involving mprovement of oxidative stress and regulation of TGF-β and NF-B.BiosciBiotechnolBiochem74 1355 1361 - 35.
L´opez-L´azaro M. 2009 Distribution and biological activities of the flavonoid luteol in Mini Rev Med Chem9 31 59 - 36.
Maritim AC, Sanders RA, and Watkins JB 3rd 2003 Diabetes, oxidative stress, and antioxidants: A review. J BiochemMolToxicol17 24 38 - 37.
Masharani U. 2008 Diabetes Mellitus and hypoglycemia, inCurrent medical diagnosis and treatment, 47 th edition (McPhee SJ, Papadakis MA, and Tierney LM, eds),1032 1073 McGraw-Hill, New York. - 38.
Matsumoto T. Kobayashi T. Wakabayashi K. Kamata K. 2005 Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats. Am J Physiol Heart CircPhysiol289: H1933 H1940. - 39.
McCord JM 1985 Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med312 159 163 - 40.
Nam SM, Lee MY, Koh JH, Park JH, Shin JY, Shin YG, Koh SB, Lee EY, and Chung CH 2009 Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: The role of reducing oxidative stress in its protective property Diabetes Res ClinPract83 176 182 - 41.
Oberley LW 1988 Free radicals and diabetes.Free RadicBiol Med5 113 124 - 42.
Ogawa S. Mori T. Nako K. Keto T. Takeuchi K. Ito S. 2006 Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. 47 699 705 - 43.
MD Oldfield Bach. L. A. Forbes J. M. Nikolic-Paterson D. Mc Robert A. Thallas V. Atkins R. C. Osicka T. Jerums G. ME Copper 2001 Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest108 1853 1863 - 44.
Park I. S. Kiyomoto H. Abboud S. L. Abboud H. E. 1997 Expression of transforming growth factor-β and type IV collagen in early streptozotocin- induced diabetes. Diabetes46 473 480 - 45.
Park JY, Ha SW, and King GL 1999 The role of protein kinase C activation in the pathogenesis of diabetic vascular complications.Perit Dial Int19: S222 S227. - 46.
Poli G. Albano E. Dianzani M. U. 1987 The role of lipid peroxidation in liver damage. ChemPhys Lipids45 117 142 - 47.
Rees DA and Alcolado JC 2005 Animal models of diabetes mellitus Diabet Med22 359 370 - 48.
Ro° sen. P. Nawroth P. P. King G. Mo° ller. W. Tritschler H. J. Packer L. 2001 The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev17 189 212 - 49.
Ross JA, and Kasum CM 2002 Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr22 19 34 - 50.
Schnackenberg CG 2002 Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature.Am J PhysiolRegulIntegr Comp Physiol282: R335 R342. - 51.
Shah IM, Mackay SP, and McKay GA 2009 Therapeutic strategies in the treatment of diabetic nephropathy- a translational medicine approach. Curr Med Chem16 997 1016 - 52.
Shah S. V. Baliga R. Rajapurkar M. Fonseca V. A. 2007 Oxidants in chronic kidney disease. J Am SocNephrol18 16 28 - 53.
Shankland S. J. Scholey J. W. Ly H. Thai K. 1994 Expression of transforming growth factor-β1 during diabetic renal hypertrophy.Kidney Int46 430 442 - 54.
Sharma K. Jin Y. Guo J. Ziyadeh F. N. 1996 Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. 45 522 530 - 55.
Sharma K. Ziyadeh F. N. Alzahabi B. Mc Gowan T. A. Kapoor S. Kurnik B. R. Kurnik P. B. Weisberg L. S. 1997 Increased renal production of transforming growth factor-beta 1 in patients with type II diabetes. Diabetes46 854 859 - 56.
Singh D. K. Winocour P. Farrington K. 2011 Oxidative stress in early diabetic nephropathy: fueling the fire Nat Rev Endocrinol7 176 184 - 57.
Stirban A. Rosen P. Tschoepe D. 2008 Complications of type 1 diabetes: new molecular findings Mt Sinai J Med75 328 351 - 58.
Takahashi S. Oida K. Fujiwara R. Maeda H. Hayashi S. Takai H. Tamai T. Nakai T. Miyabo S. 1992 Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol20 900 906 - 59.
Takebayashi K. Matsumoto S. Aso Y. Inukai T. 2006 Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab91 2214 2217 - 60.
Tseng TH, Kao TW, Chu CY, Chou FP, Lin WL, and Wang CJ 2000 Induction of apoptosis Hibiscus protocatechuic acid in human leukemia cells via reduction of retinoblastoma (RB) phosphorylation and Bcl-2 expression. Bi ochemPharmacol60 307 315 - 61.
Usui H. Shikata K. Matsuda M. Okada S. Ogawa D. Yamashita T. Hida K. Satoh M. Wada J. Makino H. 2003 HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephro. Dial Transplant18 265 272 - 62.
Vora JP, and Ibrahim HAA 2003 Clinical manifestations and natural history of diabetic nephropathy, in Comprehensive clinical nephrology, 2nd edition (Johnson RJ, and Feehally J, eds),425 437 Mosby, Edinburgh. - 63.
Wang G. G. Lu X. H. Li W. Zhao X. Zhang C. 2011 Protective effects of luteolin on diabetic nephropathy in STZ-Induced diabetic rats. Evid Based Complement Alternat Meddoi:10.1155/2011/ 323171 EOF . - 64.
Wang SC, Lee SF, Wang CJ, Lee CH, Lee WC, and Lee HJ 2009 Aqueous Extract from Hibiscus sabdariffa Linnaeus Ameliorate Diabetic Nephropathy via Regulating Oxidative Status and Akt/Bad/14-3-3{gamma} in an Experimental Animal Model. eCAM 10.1093/ecam/nep181. - 65.
Williams ME, and Stanton RC 2005 Management of diabetic kidney disease, in Joslin’s Diabetes Mellitus (Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, and Smith RJ, eds)925 949 Lippincott Williams & Wilkins, Philadelphia. - 66.
Wolf G. Sharma K. Chen Y. Ericksen M. Ziyadeh F. N. 1992 High glucose- induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int42 647 656 - 67.
Wolf G. Ziyadeh F. N. 1999 Molecular mechanisms of diabetic renal hypertrophy. Kidney Int56 393 405 - 68.
Yamamoto T. Nakamura T. Noble N. A. Ruoslahti E. Border W. A. 1993 Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. ProcNatlAcadSci USA90 1814 1818 - 69.
Zipp T. Schelling J. R. 2003 Diabetic nephropathy, in Nephrology secrets 2nd edition (Hricik DE, Miller RT, Sedor JR, eds)105 111 Hanley &Belfus Inc. Medical Publishers, Philadelphia. - 70.
Ziyadeh F. N. Hoffman B. B. Han D. C. Iglesias La Cruz. M. C. Hong S. W. Isono M. Chen S. Mc Gowan T. A. Sharma K. 2000 Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. ProcNatlAcadSci USA97 8015 8020 - 71.
Ziyadeh F. N. Sharma K. Ericksen M. Wolf G. 1994 Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by activation of transforming growth factor-β. J Clin Invest93 536 542